Benzinga's Top Upgrades
October 28, 2013 at 08:29 AM EDT
Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY ) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday. Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC ) from “sell” to
